SPORES Granted for Breast and Prostate Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 12
Volume 9
Issue 12

BETHESDA, Md-Grants totaling $12.7 million have been awarded to five institutions for new research initiatives in breast and prostate cancer. The National Cancer Institute under its SPORE program (Specialized Program of Research Excellence) will fund the projects. The money will pay for the first year of the 5-year projects. Awards went to:

BETHESDA, Md—Grants totaling $12.7 million have been awarded to five institutions for new research initiatives in breast and prostate cancer. The National Cancer Institute under its SPORE program (Specialized Program of Research Excellence) will fund the projects. The money will pay for the first year of the 5-year projects. Awards went to:

• University of California, San Francisco, where researchers led by Marc A. Shuman, MD, will undertake several projects aimed at improving treatment for advanced prostate cancer.

• A Boston-based collaborative effort of five institutions, led by James Dirk Iglehart, MD, of the Dana-Farber Cancer Institute, that will study genetic aspects of breast cancer.

• Northwestern University’s Lurie Comprehensive Cancer Center for a study led by V. Craig Jordan, PhD, of the role of diet and hormones in the prevention and development of breast cancer.

• Johns Hopkins University School of Medicine for projects headed by Nancy Davidson, MD, which include developing molecular markers for the classification and progression of breast cancer.

• University of Alabama at Birmingham where Kirby I. Bland, MD, and a team of scientists will focus on a range of breast cancer projects to develop novel retinoids for chemoprevention, understand the mechanism of tamoxifen (Nolvadex) resistance, and develop new treatments using gene therapy, DNA vaccines, and radioimmunotherapy.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.